Company Description
Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States.
The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis.
It also sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne.
The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation.
Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.
| Country | United States |
| Founded | 2014 |
| IPO Date | Nov 12, 2021 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 41 |
| CEO | Claude Maraoui |
Contact Details
Address: 9237 E Via De Ventura Blvd., Suite 105 Scottsdale, Arizona 85258 United States | |
| Phone | 480-434-6670 |
| Website | journeymedicalcorp.com |
Stock Details
| Ticker Symbol | DERM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $10.00 |
| CIK Code | 0001867066 |
| CUSIP Number | 48115J109 |
| ISIN Number | US48115J1097 |
| Employer ID | 47-1879539 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Lindsay Allan Rosenwald | Executive Chairman |
| Claude Maraoui | Founder, President, Chief Executive Officer and Director |
| Joseph M. Benesch | Interim Chief Financial Officer and Corporate Controller |
| Andrew J. Zwible | Vice President of Operations |
| Ramsey Alloush | General Counsel and Company Secretary |
| Robert Nevin | Chief Commercial Officer |
| Jaclyn Jaffe | Senior Director of Corporate Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 29, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Jan 2, 2024 | 8-K | Current Report |
| Dec 15, 2023 | S-8 | Securities to be offered to employees in employee benefit plans |
| Dec 8, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q | Quarterly Report |
| Nov 7, 2023 | 8-K | Current Report |
| Sep 26, 2023 | 8-K | Current Report |
| Sep 19, 2023 | 8-K | Current Report |
| Sep 6, 2023 | 8-K | Current Report |